Delivering the best in vivo gene editing medicine
May 12, 2025
AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy
Read more
Positively Transforming Patient's Life with Genome Editing
BREAKING THE GROUND FOR PATIENTS IN NEED
First in China: safe and effective systemic CRISPR gene editing in humans
Proven capability and track record to deliver innovative products in China and the US in industry-leading speed
PRODUCT WITH AN EDGE
Potentially best-in-class in vivo gene editing product for ATTR
> 90% serum TTR reduction after 4 weeks
No off target editing detected at up to ~80 times of EC90
No infusion-related reaction observed
No > Grade 1 liver enzyme elevation observed
PLATFORM THAT PERFORMS
Industry-leading end-to-end in vivo gene editing platform
RNA synthesis (Research and GMP grade)
Editing (Patented base editors and Cas enzymes; industry-leading capability of gRNA screening and optimization)
Delivery (Industry-leading efficiency and specificity)